163 related articles for article (PubMed ID: 37570809)
21. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
[TBL] [Abstract][Full Text] [Related]
22. Targeting the neonatal fc receptor for antigen delivery using engineered fc fragments.
Mi W; Wanjie S; Lo ST; Gan Z; Pickl-Herk B; Ober RJ; Ward ES
J Immunol; 2008 Dec; 181(11):7550-61. PubMed ID: 19017944
[TBL] [Abstract][Full Text] [Related]
23. Image-Based Dosimetry in Dogs and Cross-Reactivity with Human Tissues of IGF2R-Targeting Human Antibody.
Allen KJH; Kwon O; Hutcheson MR; Grudzinski JJ; Cain SM; Cruz FA; Vinayakamoorthy RM; Sun YS; Fairley L; Prabaharan CB; Dickinson R; MacDonald-Dickinson V; Uppalapati M; Bednarz BP; Dadachova E
Pharmaceuticals (Basel); 2023 Jul; 16(7):. PubMed ID: 37513891
[TBL] [Abstract][Full Text] [Related]
24. Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease.
Petkova SB; Akilesh S; Sproule TJ; Christianson GJ; Al Khabbaz H; Brown AC; Presta LG; Meng YG; Roopenian DC
Int Immunol; 2006 Dec; 18(12):1759-69. PubMed ID: 17077181
[TBL] [Abstract][Full Text] [Related]
25. Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates.
Yeung YA; Leabman MK; Marvin JS; Qiu J; Adams CW; Lien S; Starovasnik MA; Lowman HB
J Immunol; 2009 Jun; 182(12):7663-71. PubMed ID: 19494290
[TBL] [Abstract][Full Text] [Related]
26. Development of a label-free FcRn-mediated transcytosis assay for in vitro characterization of FcRn interactions with therapeutic antibodies and Fc-fusion proteins.
Chung S; Lin YL; Nguyen V; Kamen L; Zheng K; Vora B; Song A
J Immunol Methods; 2018 Nov; 462():101-105. PubMed ID: 30030147
[TBL] [Abstract][Full Text] [Related]
27. Extending human IgG half-life using structure-guided design.
Booth BJ; Ramakrishnan B; Narayan K; Wollacott AM; Babcock GJ; Shriver Z; Viswanathan K
MAbs; 2018 Oct; 10(7):1098-1110. PubMed ID: 29947573
[TBL] [Abstract][Full Text] [Related]
28. Analytical FcRn affinity chromatography for functional characterization of monoclonal antibodies.
Schlothauer T; Rueger P; Stracke JO; Hertenberger H; Fingas F; Kling L; Emrich T; Drabner G; Seeber S; Auer J; Koch S; Papadimitriou A
MAbs; 2013; 5(4):576-86. PubMed ID: 23765230
[TBL] [Abstract][Full Text] [Related]
29. A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life.
Souders CA; Nelson SC; Wang Y; Crowley AR; Klempner MS; Thomas W
MAbs; 2015; 7(5):912-21. PubMed ID: 26018774
[TBL] [Abstract][Full Text] [Related]
30. Binding structures and energies of the human neonatal Fc receptor with human Fc and its mutants by molecular modeling and dynamics simulations.
Huang X; Zheng F; Zhan CG
Mol Biosyst; 2013 Dec; 9(12):3047-58. PubMed ID: 24057047
[TBL] [Abstract][Full Text] [Related]
31. The influence of antibody engineering on Fc conformation and Fc receptor binding properties: Analysis of FcRn-binding engineered antibodies and an Fc fusion protein.
Suzuki T; Hashii N; Tada M; Ishii-Watabe A
MAbs; 2021; 13(1):1923366. PubMed ID: 34030575
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics of novel Fc-engineered monoclonal and multispecific antibodies in cynomolgus monkeys and humanized FcRn transgenic mouse models.
Valente D; Mauriac C; Schmidt T; Focken I; Beninga J; Mackness B; Qiu H; Vicat P; Kandira A; Radošević K; Rao S; Darbyshire J; Kabiri M
MAbs; 2020; 12(1):1829337. PubMed ID: 33079615
[TBL] [Abstract][Full Text] [Related]
33. A Minimal Physiologically Based Pharmacokinetic Model with a Nested Endosome Compartment for Novel Engineered Antibodies.
Yuan D; Rode F; Cao Y
AAPS J; 2018 Mar; 20(3):48. PubMed ID: 29541870
[TBL] [Abstract][Full Text] [Related]
34. Mapping the site on human IgG for binding of the MHC class I-related receptor, FcRn.
Kim JK; Firan M; Radu CG; Kim CH; Ghetie V; Ward ES
Eur J Immunol; 1999 Sep; 29(9):2819-25. PubMed ID: 10508256
[TBL] [Abstract][Full Text] [Related]
35. Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity?
Gurbaxani B; Dostalek M; Gardner I
Mol Immunol; 2013 Dec; 56(4):660-74. PubMed ID: 23917469
[TBL] [Abstract][Full Text] [Related]
36. Biophysical differences in IgG1 Fc-based therapeutics relate to their cellular handling, interaction with FcRn and plasma half-life.
Gjølberg TT; Frick R; Mester S; Foss S; Grevys A; Høydahl LS; Jørstad ØK; Schlothauer T; Sandlie I; Moe MC; Andersen JT
Commun Biol; 2022 Aug; 5(1):832. PubMed ID: 35982144
[TBL] [Abstract][Full Text] [Related]
37. Roles of Fc Domain and Exudation in L2 Antibody-Mediated Protection against Human Papillomavirus.
Wang JW; Wu WH; Huang TC; Wong M; Kwak K; Ozato K; Hung CF; Roden RBS
J Virol; 2018 Aug; 92(15):. PubMed ID: 29743371
[TBL] [Abstract][Full Text] [Related]
38. The effect of the neonatal Fc receptor on human IgG biodistribution in mice.
Chen N; Wang W; Fauty S; Fang Y; Hamuro L; Hussain A; Prueksaritanont T
MAbs; 2014; 6(2):502-8. PubMed ID: 24492305
[TBL] [Abstract][Full Text] [Related]
39. Design and characterization of novel dual Fc antibody with enhanced avidity for Fc receptors.
Goulet DR; Zwolak A; Williams JA; Chiu ML; Atkins WM
Proteins; 2020 May; 88(5):689-697. PubMed ID: 31702857
[TBL] [Abstract][Full Text] [Related]
40. Mechanism-Based Competitive Binding Model to Investigate the Effect of Neonatal Fc Receptor Binding Affinity on the Pharmacokinetic of Humanized Anti-VEGF Monoclonal IgG1 Antibody in Cynomolgus Monkey.
Ng CM; Fielder PJ; Jin J; Deng R
AAPS J; 2016 Jul; 18(4):948-59. PubMed ID: 27075465
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
